11.30.22 -- My Path From The Clinic, To Research, To Biotech Leadership
Sponsor
With our new Cellvento® 4HEK medium, you can produce higher AAV titers across multiple HEK293 cell lines, maximize production of full capsids of AAV, support robust cell growth, facilitate transfection of multiple HEK293 lineages, and thus save time in bringing your gene therapy to life! Learn more.
If years of research show us anything, it is that beyond ability and strength, there lies the hidden reality of tapping into the rich sea of needs and preferred working environments that produce empowerment and commitment.
I never thought I would leave academia. However, “a knock” on my career door presented me with an opportunity to join a biotech company with cell-free DNA testing. I considered my options carefully, spoke with family and mentors, and made the leap earlier this year.
What can we do to accelerate biosimilars’ path to market without compromising quality or safety? While clinical changes would likely take years, if not decades, to implement, innovations in CMC protocols may provide near-term solutions.
Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and genitourinary tumors. On the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D., offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker — the capacity to manufacture RNA in-house. This conversation with a scientist-turned-chief business officer is a can't-miss episode!
We evaluated and compared HyClone characterized FBS originating from the United States, New Zealand, and Australia for cell culture and production performance.
Middlesex County, NJ, is a hotbed for the life sciences, offering a deep talent pool, an extensive R&D presence, and dedicated backing by local government in the form of strategic investment.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
